| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1038826231 |
| P356 | DOI | 10.1007/S12032-012-0343-4 |
| P698 | PubMed publication ID | 23263828 |
| P50 | author | Yousheng Mao | Q73120564 |
| P2093 | author name string | Yan Sun | |
| Yi Zhou | |||
| Jing Huang | |||
| Ningzhi Xu | |||
| Jie He | |||
| Tao Qu | |||
| Hongxia Zhu | |||
| Jinwan Wang | |||
| Lanping Quan | |||
| Puyuan Xing | |||
| Hongtu Zhang | |||
| P2860 | cites work | Cancer statistics, 2010 | Q27860525 |
| Global cancer statistics, 2002 | Q27860562 | ||
| Bi-weekly chemotherapy of paclitaxel and cisplatin in patients with metastatic or recurrent esophageal cancer | Q33367836 | ||
| Chemotherapy with cisplatin and paclitaxel in patients with locally advanced, recurrent or metastatic oesophageal cancer | Q33503431 | ||
| DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy | Q34564091 | ||
| High ERCC1 expression predicts cisplatin-based chemotherapy resistance and poor outcome in unresectable squamous cell carcinoma of head and neck in a betel-chewing area | Q34769944 | ||
| Phase II study of bi-weekly administration of paclitaxel and cisplatin in patients with advanced oesophageal cancer | Q36644156 | ||
| Prognostic factors for survival in patients with advanced oesophageal cancer treated with cisplatin-based combination chemotherapy | Q36648089 | ||
| Cancer incidence and mortality in china, 2006. | Q36654618 | ||
| Palliative chemotherapy for recurrent and metastatic esophageal cancer | Q36908846 | ||
| Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie. | Q45956359 | ||
| Optimal two-stage designs for phase II clinical trials | Q46412217 | ||
| ERCC1 protein expression predicts the response of cisplatin-based neoadjuvant chemotherapy in non-small-cell lung cancer | Q46974513 | ||
| Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus | Q72683495 | ||
| Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer | Q73707393 | ||
| [Phase II study of paclitaxel and cisplatin for advanced squamous-cell carcinoma of esophagus] | Q81445733 | ||
| Thymidine synthase, thymidine phosphorylase, and excision repair cross-complementation group 1 expression as predictive markers of capecitabine plus cisplatin chemotherapy as first-line treatment for patients with advanced oesophageal squamous cell | Q84715355 | ||
| P433 | issue | 1 | |
| P921 | main subject | cisplatin | Q412415 |
| paclitaxel | Q423762 | ||
| squamous cell carcinoma | Q681817 | ||
| chemotherapy | Q974135 | ||
| esophageal squamous cell carcinoma | Q108442577 | ||
| P304 | page(s) | 343 | |
| P577 | publication date | 2012-12-21 | |
| P1433 | published in | Medical Oncology | Q2152666 |
| P1476 | title | A phase II study of biweekly paclitaxel and cisplatin chemotherapy for recurrent or metastatic esophageal squamous cell carcinoma: ERCC1 expression predicts response to chemotherapy | |
| P478 | volume | 30 |
| Q33433296 | A Retrospective Comparison of Taxane and Fluorouracil-based Chemoradiotherapy in Patients with Inoperable Esophageal Squamous Cell Carcinoma |
| Q33649971 | Adjuvant chemotherapy with paclitaxel and cisplatin in lymph node-positive thoracic esophageal squamous cell carcinoma. |
| Q57111625 | Apatinib combined with docetaxel as a salvage treatment for metastatic esophageal squamous cancer: a case report |
| Q91789465 | Association Between Multiple Lines of Active Therapy and Prognosis in Esophageal Squamous Cell Carcinoma |
| Q37701220 | Association between XRCC1 and ERCC1 single-nucleotide polymorphisms and the efficacy of concurrent radiochemotherapy in patients with esophageal squamous cell carcinoma |
| Q33778324 | Combined chemotherapy plus endostar with sequential stereotactic radiotherapy as salvage treatment for recurrent esophageal cancer with severe dyspnea: A case report and review of the literature |
| Q34142322 | ERCC1 single nucleotide polymorphism C8092A, but not its expression is associated with survival of esophageal squamous cell carcinoma patients from Fujian province, China |
| Q33788010 | Enhanced cancer stem cell properties of a mitotically quiescent subpopulation of p75NTR-positive cells in esophageal squamous cell carcinoma |
| Q64083836 | Irinotecan plus S-1 versus S-1 in patients with previously treated recurrent or metastatic esophageal cancer (ESWN 01): a prospective randomized, multicenter, open-labeled phase 3 trial |
| Q38704834 | Irinotecan plus fluorouracil-based regimen as second or third-line chemotherapy for recurrent or metastatic esophageal squamous cell carcinoma |
| Q90270769 | Lactate dehydrogenase and baseline markers associated with clinical outcomes of advanced esophageal squamous cell carcinoma patients treated with camrelizumab (SHR-1210), a novel anti-PD-1 antibody |
| Q92874852 | New Insights into Mechanisms of Cisplatin Resistance: From Tumor Cell to Microenvironment |
| Q36996728 | New and emerging combination therapies for esophageal cancer |
| Q37382552 | Paclitaxel plus cisplatin vs. 5-fluorouracil plus cisplatin as first-line treatment for patients with advanced squamous cell esophageal cancer |
| Q37269426 | Predictive value of EGFR overexpression and gene amplification on icotinib efficacy in patients with advanced esophageal squamous cell carcinoma |
| Q90157690 | Refractory solitary cervical lymph node metastasis after esophageal squamous cell carcinoma surgery and its successful treatment with immune checkpoint inhibitor: A case report and literature review |
| Q37536887 | Study of single nucleotide polymorphisms of FBW7 and its substrate genes revealed a predictive factor for paclitaxel plus cisplatin chemotherapy in Chinese patients with advanced esophageal squamous cell carcinoma |
| Q42025252 | Unusual delayed presentation of diaphragmatic hernia complicated by transverse colon and total small-bowel obstruction after postoperative chemotherapy of esophageal cancer |
Search more.